Roivant Sciences Ltd.
ROIV
Rank in Stocks
#978
Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company... Roivant Sciences Ltd. is a biopharmaceutical and healthcare technology company dedicated to discovering and advancing innovative therapeutic drugs. The firm's development pipeline targets a broad spectrum of diseases, including various forms of solid tumors and oncologic malignancies, hematological disorders like sickle cell disease and warm autoimmune hemolytic anemia, as well as rare conditions such as hypophosphatasia. Additionally, Roivant is developing treatments for immunological and dermatological ailments, including psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, thyroid eye diseases, and sarcoidosis, alongside tackling infections like staph aureus bacteremia. Founded in 2014, its operations are based in London, United Kingdom.
Share Price
$33.73
Last synced: 2026-07-31
Market Cap
$24.37B
Change (1 day)
-2.28%
Change (1 year)
90.15%
Country
GB
Trade Roivant Sciences Ltd. (ROIV)
Category
Healthcare
Revenue for Roivant Sciences Ltd. (ROIV)
Revenue in Jun 2026 TTM: $7.53M
According to Roivant Sciences Ltd. latest financial reports the company's current revenue (TTM) is $7.53M. In 2024 the company made a revenue of $32.71M a decrease compared to the revenue in the year 2023 that was $61.28M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Roivant Sciences Ltd. from 2020 to 2026
Revenue at the end of each year
| Year | Revenue | Change |
|---|---|---|
| 2026 (TTM) | $7.53M | -74.07% |
| 2025 | $29.05M | -11.19% |
| 2024 | $32.71M | -46.62% |
| 2023 | $61.28M | 10.84% |
| 2022 | $55.29M | 132.34% |
| 2021 | $23.80M | -64.85% |
| 2020 | $67.69M | 0.00% |
Revenue for similar companies or competitors
| Company | Revenue | Revenue Difference | Country |
|---|---|---|---|
| $12.62B | 167,508.87% |
US
|
|
| $2.23B | 29,480.46% |
US
|
|
| $15.74B | 208,932.49% |
AU
|
|
| - | - |
CH
|
|
| $6.02B | 79,842.74% |
NL
|
